Bioclinical markers in breast cancer: updates and perspectives.
暂无分享,去创建一个
Davide Lombardi | M. Berretta | D. Lombardi | A. Cappellani | Bruno Cacopardo | Andrea Cavallaro | Alessandro Cappellani | B. Cacopardo | A. Zanghì | M. Di Vita | Maria Di Vita | Massimiliano Berretta | Antonio Zanghi | Emanuele Lo Menzo | E. Lo Menzo | A. Cavallaro
[1] Carlos Caldas,et al. Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer , 2008, BMC Cancer.
[2] Q. Chu,et al. Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC) , 2008, Breast Cancer Research and Treatment.
[3] Arndt Hartmann,et al. Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients , 2008, Breast Cancer Research.
[4] J. Forbes,et al. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] C. Schubert,et al. Cytokine Comparisons Between Women With Breast Cancer and Women With a Negative Breast Biopsy , 2008, Nursing research.
[6] S. Paik,et al. Development of the 21-gene assay and its application in clinical practice and clinical trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Marta Cuadros,et al. Systematic Review of HER2 Breast Cancer Testing , 2009, Applied immunohistochemistry & molecular morphology : AIMM.
[9] Gianluca Bontempi,et al. Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes , 2008, Clinical Cancer Research.
[10] Ian O Ellis,et al. Basal-like breast cancer: a critical review. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] O. Olopade,et al. Advances in Breast Cancer: Pathways to Personalized Medicine , 2008, Clinical Cancer Research.
[12] A. Scorilas,et al. Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer. , 2008, The oncologist.
[13] L. Carey,et al. What is triple-negative breast cancer? , 2008, European journal of cancer.
[14] N. Brünner,et al. TIMP-1 as a tumor marker in breast cancer – An update , 2008, Acta oncologica.
[15] J. Kurebayashi. [Biomarkers in breast cancer]. , 2004, Gan to kagaku ryoho. Cancer & chemotherapy.
[16] L. Demers,et al. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] L. Murphy,et al. Estrogen receptor alpha negative breast cancer patients: Estrogen receptor beta as a therapeutic target , 2008, The Journal of Steroid Biochemistry and Molecular Biology.
[18] Peter Kraft,et al. Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics , 2008, PLoS genetics.
[19] F. Schmitt,et al. EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy , 2008, Expert review of molecular diagnostics.
[20] J. Baselga,et al. Targeted therapies in breast cancer: where are we now? , 2008, European journal of cancer.
[21] M. Sormani,et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. , 2008, Journal of the National Cancer Institute.
[22] Mai Brooks,et al. Breast cancer screening and biomarkers. , 2009, Methods in molecular biology.
[23] C. Perou,et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.
[24] N. Sneige,et al. Triple Negative Breast Carcinoma and the Basal Phenotype: From Expression Profiling to Clinical Practice , 2007, Advances in anatomic pathology.
[25] R. Neve,et al. Unraveling the biologic and clinical complexities of HER2. , 2008, Clinical breast cancer.
[26] S. Stein,et al. Drug Insight: intracellular inhibitors of HER2—clinical development of lapatinib in breast cancer , 2008, Nature Clinical Practice Oncology.
[27] P. Birembaut,et al. Prognostic value of a proliferation index including MIB1 and argyrophilic nucleolar organizer regions proteins in node-negative breast cancer. , 2008, American journal of obstetrics and gynecology.
[28] J. Benítez,et al. The Molecular Pathology of Hereditary Breast Cancer , 2008, Pathobiology.
[29] P. Drew,et al. Potential prognostic and therapeutic roles for cytokines in breast cancer (Review). , 2006, Oncology reports.
[30] M. Wicha. Cancer stem cell heterogeneity in hereditary breast cancer , 2008, Breast Cancer Research.
[31] M. Georgescu. NHERF1: molecular brake on the PI3K pathway in breast cancer , 2008, Breast Cancer Research.
[32] P. Muti,et al. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. , 2006, Biochimica et biophysica acta.
[33] F. Puglisi,et al. Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] P. Nowell,et al. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. , 1984, Science.
[35] B. Riche,et al. Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator. , 2008, Clinical breast cancer.
[36] S. Koscielny. Critical review of microarray-based prognostic tests and trials in breast cancer , 2008, Current opinion in obstetrics & gynecology.
[37] Samuel Leung,et al. Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2008, Clinical Cancer Research.
[38] C. Boetes,et al. Breast MRI: guidelines from the European Society of Breast Imaging , 2008, European Radiology.
[39] Marc Tischkowitz,et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer , 2007, BMC Cancer.
[40] R. Nahta,et al. Her2 cross talk and therapeutic resistance in breast cancer. , 2008, Frontiers in bioscience : a journal and virtual library.
[41] Sami Kilpinen,et al. Role of ErbB4 in Breast Cancer , 2008, Journal of Mammary Gland Biology and Neoplasia.
[42] F. Esteva,et al. Her2-positive breast cancer: herceptin and beyond. , 2008, European journal of cancer.
[43] J. Bergh,et al. Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series , 2007, Clinical Cancer Research.
[44] B. Henderson,et al. Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort , 2009, BMC Cancer.
[45] J. Foekens,et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] R. Bast,et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] D. Stern. ERBB3/HER3 and ERBB2/HER2 Duet in Mammary Development and Breast Cancer , 2008, Journal of Mammary Gland Biology and Neoplasia.
[48] J. Khatcheressian,et al. Breast cancer follow-up in the adjuvant setting , 2008, Current oncology reports.
[49] C. Singer,et al. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies. , 2008, Biochimica et biophysica acta.
[50] I. Ellis,et al. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. , 2005, Endocrine-related cancer.
[51] F. Monti,et al. p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[52] J. Foekens,et al. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] H. Gómez,et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] J. Bartlett,et al. Predictive markers in breast cancer – the future , 2007, Histopathology.
[55] Alice S Whittemore,et al. Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. , 2007, JAMA.
[56] Lajos Pusztai,et al. Current status of prognostic profiling in breast cancer. , 2008, The oncologist.
[57] J. Sirvent,et al. Prognostic value of apoptosis in breast cancer (pT1-pT2). A TUNEL, p53, bcl-2, bag-1 and Bax immunohistochemical study. , 2004, Histology and histopathology.
[58] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.
[59] D. Dabbs,et al. Luminal B breast tumors are not HER2 positive , 2008, Breast Cancer Research.
[60] G. Colditz,et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer , 2008, Breast Cancer Research.
[61] M. Dowsett,et al. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[62] S. Kesari,et al. Breast cancer surface receptors predict risk for developing brain metastasis and subsequent prognosis , 2008, Breast Cancer Research.
[63] S. Ménard,et al. Biology, prognosis and response to therapy of breast carcinomas according to HER2 score. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[64] C Caldas,et al. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. , 2008, Breast.
[65] D. Larsimont,et al. Class III β-Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel , 2008, Clinical Cancer Research.
[66] Max S Wicha,et al. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] Jerry Younger,et al. VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy , 2008, Clinical Cancer Research.
[68] A. Rim,et al. Trends in breast cancer screening and diagnosis. , 2008, Cleveland Clinic journal of medicine.
[69] A. Glas,et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study , 2009, Breast Cancer Research and Treatment.
[70] Passeig Vall d'Hebron. Targeted therapies in breast cancer: Where are we now? , 2008 .
[71] V. Heinemann,et al. Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge. , 2008, The oncologist.
[72] G. Giles,et al. Design and analysis issues in a population-based, case-control-family study of the genetic epidemiology of breast cancer and the Co-operative Family Registry for Breast Cancer Studies (CFRBCS). , 1999, Journal of the National Cancer Institute. Monographs.
[73] J. Henson,et al. Survival in patients with brain metastases from breast cancer , 2008, Cancer.
[74] H. Uno,et al. Development and verification of a prediction model using serum tumor markers to predict the response to chemotherapy of patients with metastatic or recurrent breast cancer , 2008, Journal of Cancer Research and Clinical Oncology.
[75] G. Botti,et al. Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era. , 2008, Clinical breast cancer.
[76] Barbara McGrogan,et al. Taxanes, microtubules and chemoresistant breast cancer. , 2008, Biochimica et biophysica acta.
[77] J. Foekens,et al. DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and , 2007, European journal of cancer.
[78] J. R. Reeves,et al. Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer , 2003, The Journal of pathology.
[79] C. Nguyen,et al. A candidate molecular signature associated with tamoxifen failure in primary breast cancer , 2008, Breast Cancer Research.
[80] D. Plewes,et al. Systematic Review: Using Magnetic Resonance Imaging to Screen Women at High Risk for Breast Cancer , 2008, Annals of Internal Medicine.
[81] Jill M Kolesar,et al. Gene-expression assays: new tools to individualize treatment of early-stage breast cancer. , 2008, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[82] L. Pusztai,et al. Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[83] H. McArthur. An overview of HER-targeted therapy with lapatinib in breast cancer , 2009, Advances in therapy.
[84] M. Piccart-Gebhart,et al. HER-2 positive breast cancer: what else beyond trastuzumab-based therapy? , 2008, Anti-cancer agents in medicinal chemistry.
[85] S. Küçücük,et al. Lower Level of MAPK Expression Is Associated with Anthracycline Resistance and Decreased Survival in Patients with Hormone Receptor Negative Breast Cancer , 2008, Cancer investigation.
[86] T. Curran,et al. FBJ murine osteosarcoma virus: identification and molecular cloning of biologically active proviral DNA , 1982, Journal of virology.
[87] J. Meza,et al. The molecular etiology of breast cancer: Evidence from biomarkers of risk , 2007, International journal of cancer.
[88] A. Jemal,et al. Global Cancer Statistics , 2011 .
[89] S Gori,et al. Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[90] M. Cristofanilli,et al. Integrating Circulating Tumor Cell Assays into the Management of Breast Cancer , 2007, Current treatment options in oncology.
[91] D. Ross,et al. Chemosensitivity and Stratification by a Five Monoclonal Antibody Immunohistochemistry Test in the NSABP B14 and B20 Trials , 2008, Clinical Cancer Research.
[92] D. Mavroudis,et al. Circulating tumor cells in breast cancer , 2008, Current opinion in obstetrics & gynecology.
[93] S. Fox,et al. Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[94] M. Daidone,et al. Clinical studies of Bcl-2 and treatment benefit in breast cancer patients. , 1999, Endocrine-related cancer.
[95] D. Hicks,et al. Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing. , 2009, Archives of pathology & laboratory medicine.
[96] A. D. Van den Abbeele,et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[97] A. Harris,et al. Targeting tumour hypoxia in breast cancer. , 2008, European journal of cancer.
[98] L. Mariani,et al. Serial determination of CEA and CA 15.3 in breast cancer follow-up: An assessment of their diagnostic accuracy for the detection of tumour recurrences , 2009, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.
[99] J. Baak,et al. Proliferation accurately identifies the high-risk patients among small, low-grade, lymph node-negative invasive breast cancers. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[100] A. Hamburger. The Role of ErbB3 and its Binding Partners in Breast Cancer Progression and Resistance to Hormone and Tyrosine Kinase Directed Therapies , 2008, Journal of Mammary Gland Biology and Neoplasia.
[101] Charles M. Perou,et al. Triple-Negative Breast Cancer: Risk Factors to Potential Targets , 2008, Clinical Cancer Research.
[102] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[103] R. Gelber,et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[104] J. Baselga,et al. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2 , 2008, Nature Clinical Practice Oncology.
[105] F. Esteva,et al. Serum HER‐2/neu and relative resistance to trastuzumab‐based therapy in patients with metastatic breast cancer , 2008, Cancer.
[106] M. Ellis,et al. Can Molecular Markers Predict When to Implement Treatment With Aromatase Inhibitors in Invasive Breast Cancer , 2006 .
[107] J. Foekens,et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.
[108] N. Saijo,et al. A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer , 2009, International Journal of Clinical Oncology.
[109] H. Mouridsen,et al. The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D , 2008, Acta oncologica.
[110] I. Ellis,et al. Impact of Basal-Like Breast Carcinoma Determination for a More Specific Therapy , 2008, Pathobiology.